Sofosbuvir molecular structure

Sofosbuvir

Also known as: Sovaldi, MyHep, Hepcinat, Sofovir, Resof (component of Harvoni and Epclusa)

CAS Number: 1190307-88-0

Antiviral (HCV NS5B Polymerase Inhibitor)

Pharmacopeia Standards

USPIP

Mechanism of Action

Sofosbuvir is a phosphoramidate ProTide prodrug of a 2-deoxy-2-fluoro-2-methyluridine monophosphate that bypasses the rate-limiting first phosphorylation step in hepatocytes. Intracellular hydrolysis by cathepsin A and HINT1 followed by kinase action generates the uridine triphosphate analogue. This triphosphate is incorporated by the hepatitis C NS5B RNA-dependent RNA polymerase and acts as a chain terminator across all major HCV genotypes.

Technical Specifications

Generic / INN NameSofosbuvir
CAS Registry Number1190307-88-0
Molecular FormulaC22H29FN3O9P
Molecular Weight529.45 g/mol g/mol
Typical PurityNot less than 98.5% by HPLC; diastereomeric purity not less than 99.0%
Storage ConditionsStore below 25 degrees C in tightly closed containers with desiccant, protected from light and moisture.
Shelf Life36 months from date of manufacture in original sealed packing
CategoryAntivirals

Specifications are indicative and intended for sourcing reference only. Always confirm against the supplier's Certificate of Analysis and the applicable pharmacopeial monograph before issuing a purchase specification.

Typical Applications

Bulk API for 400 mg tablets and for pan-genotypic fixed-dose combinations with velpatasvir, ledipasvir or daclatasvir used in direct-acting antiviral hepatitis C treatment programmes.

Manufacturers (0+)

View all →
No manufacturers listed yet. Register your company to appear here.